Sanofi’s Sarclisa Gets EMA Backing In Myeloma, Mirroring FDA OK
But Experts Doubt It Can Overtake J&J’s Entrenched Darzalex
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.
You may also be interested in...
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.